Skip to main content
Erschienen in: Supportive Care in Cancer 8/2023

01.08.2023 | Research

Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series

verfasst von: Jackeline Mayara Inácio Magalhães, Fabiana Moura da Motta Silveira, Luciana Silva Regueira, Douglas Felipe de Lima e Silva, Samuel Rodrigo de Andrade Veras, Maria Júlia Gonçalves de Mello

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the prophylaxis effect of pentoxifylline and tocopherol (PENTO) on the frequency and severity of medication-related osteonecrosis of the jaw (MRONJ) diagnosed at three months in patients with cancer submitted to tooth extractions during the treatment with bone-modifying agents.

Methods

This case series was conducted at the outpatient dental clinic of the Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) between April 2021 and April 2022. Patients ≥ 18 years old were included; those with maxillary metastasis or who performed head or neck radiotherapy were excluded. The PENTO protocol was prescribed two weeks before and two weeks after the tooth extraction, and patients were reassessed one week, one month, and three months after the extraction. The main outcome was the development of MRONJ.

Results

Of the 114 screened patients, 17 were included; they were aged between 43 and 73 years and were mostly female (88.2%). Thirty-two tooth extractions were performed (22 in the maxilla and 10 in the mandible). Breast cancer was the most predominant neoplasm (70.6%), being metastatic in 35.3% of patients. Also, all patients used intravenous bisphosphonates. Stage 1 MRONJ was diagnosed in three patients (17.6%), representing three (9.4%) of all tooth extractions. The repair of MRONJ was achieved 30 days after the PENTO protocol.

Conclusion

The prophylaxis use of PENTO reduced the severity of injuries, was well-tolerated, and showed patient compliance.
Literatur
6.
Zurück zum Zitat Fleisher KE, Kontio R, Otto S (2016) Antiresorptive drug-related osteonecrosis of the jaw (ARONJ)—a guide to research. AOCMF publication, Dübendorf, Suíça Fleisher KE, Kontio R, Otto S (2016) Antiresorptive drug-related osteonecrosis of the jaw (ARONJ)—a guide to research. AOCMF publication, Dübendorf, Suíça
11.
Zurück zum Zitat Moutte MÊS (2017) Osteonecrose maxilo-mandibular induzida por bisfosfonatos, Almada, Portugal. Dissertação [Mestrado Integrado em Medicina Dentária] - Instituto Superior De Ciências Da Saúde Egas Moniz Moutte MÊS (2017) Osteonecrose maxilo-mandibular induzida por bisfosfonatos, Almada, Portugal. Dissertação [Mestrado Integrado em Medicina Dentária] - Instituto Superior De Ciências Da Saúde Egas Moniz
20.
Zurück zum Zitat Hupp JR, Elis E, Tucker MR (2015) Cirurgia Oral e Maxilofacial Contemporânea. 6ª ed. Rio de Janeiro, Brasil: GEN Guanabara Koogan Hupp JR, Elis E, Tucker MR (2015) Cirurgia Oral e Maxilofacial Contemporânea. 6ª ed. Rio de Janeiro, Brasil: GEN Guanabara Koogan
29.
Metadaten
Titel
Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series
verfasst von
Jackeline Mayara Inácio Magalhães
Fabiana Moura da Motta Silveira
Luciana Silva Regueira
Douglas Felipe de Lima e Silva
Samuel Rodrigo de Andrade Veras
Maria Júlia Gonçalves de Mello
Publikationsdatum
01.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-023-07906-0

Weitere Artikel der Ausgabe 8/2023

Supportive Care in Cancer 8/2023 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.